Feng Yi, Ju Hui, Yang Baxian, An Haiyan
Department of Anesthesiology, Peking University People's Hospital, Beijing, People's Republic of China.
J Pain. 2008 Jan;9(1):45-52. doi: 10.1016/j.jpain.2007.08.003. Epub 2007 Oct 18.
The goal of this study was to evaluate the systemic and peripheral effects of preoperative administration of cyclooxygenase-2 inhibitor on pain and inflammation occurring with total knee replacement (TKR). Patients undergoing elective TKR were prospectively and randomly given oral rofecoxib (25 mg) or placebo (control group) 1 hour before surgery. All patients received an epidural combined with isoflurane anesthesia during the operation and patient-controlled epidural analgesia postoperatively. The outcome measures included pain scores during rest and movement of knee joints and cumulative morphine consumption. Femoral blood and knee joint drainage fluids were examined for leucocyte numbers and concentrations of cytokines (including IL-6, IL-8, IL-10, and TNF-alpha). Periarticular circumferential increments at 48 hours served as an indication of inflammatory edema. Pain scores during rest and knee joint movement on postoperative days 1 and 2 were better in those given rofecoxib than in control subjects, and cumulative morphine consumption for the first 24 hours was significantly reduced. Both groups had higher concentrations of IL-6 and IL-8 in knee drainage fluid compared with serum levels. Rofecoxib significantly decreased regional IL-6 and TNF-alpha level after surgery. Moreover, the incidence of febris and degree of local edema were lower in the rofecoxib group (P < .05), and peripheral IL-6 level significantly correlated with pain score at 48 hours. Preoperative administration of rofecoxib increases patient satisfaction with analgesia, reduces opioid requirement, and decreases both systemic and local anti-inflammation after TKR.
This randomized, double-blinded trial shows that preoperative administration of rofecoxib can greatly ameliorate the pain occurring with total knee joint replacement surgery and its accompanying reduction of general and local inflammatory reactions.
本研究的目的是评估术前给予环氧化酶-2抑制剂对全膝关节置换术(TKR)时疼痛和炎症的全身及外周影响。择期行TKR的患者在手术前1小时被前瞻性随机给予口服罗非昔布(25毫克)或安慰剂(对照组)。所有患者在手术期间接受硬膜外联合异氟烷麻醉,术后接受患者自控硬膜外镇痛。观察指标包括膝关节休息和活动时的疼痛评分以及吗啡累积用量。检测股静脉血和膝关节引流液中的白细胞数量及细胞因子(包括IL-6、IL-8、IL-10和TNF-α)浓度。48小时时关节周围周径增加作为炎症性水肿的指标。服用罗非昔布的患者术后第1天和第2天膝关节休息和活动时的疼痛评分优于对照组,且前24小时吗啡累积用量显著减少。与血清水平相比,两组膝关节引流液中IL-6和IL-8浓度均较高。罗非昔布显著降低术后局部IL-6和TNF-α水平。此外,罗非昔布组发热发生率和局部水肿程度较低(P < .05),外周IL-6水平与48小时时的疼痛评分显著相关。术前给予罗非昔布可提高患者对镇痛的满意度,减少阿片类药物需求,并降低TKR后的全身和局部炎症反应。
这项随机双盲试验表明,术前给予罗非昔布可极大地改善全膝关节置换手术时出现的疼痛及其伴随的全身和局部炎症反应的减轻。